Source link : https://www.newshealth.biz/health-news/adding-daratumumab-to-vrd-boosts-mrd-negativity-in-transplant-ineligible-myeloma/
In an analysis of the phase III CEPHEUS trial presented at the American Society of Hematology annual meeting, adding daratumumab (Darzalex) to bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) significantly improved rates of minimal residual disease (MRD)-negativity and progression-free survival in newly diagnosed multiple myeloma patients ineligible for stem cell transplant. In this exclusive MedPage […]
Author : News Health
Publish date : 2024-12-23 16:56:36
Copyright for syndicated content belongs to the linked Source.